Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Development of a dosimetric model for in vitro labelled cells with β + emitters in PET tracking studies.

Jacquemin M, Broggio D, Franck D, Desbrée A.

Phys Med Biol. 2019 Aug 7;64(15):155015. doi: 10.1088/1361-6560/ab2cbe.

PMID:
31239425
2.

The concentration of GPIbα magnetic particles is a critical parameter occasionally responsible for poor reproducibility of the VWF:GPIbR chemiluminescent immunoassay.

Calcoen B, Van Horenbeeck I, Debasse M, Toelen J, Vanlinthout I, Schoeters J, Peerlinck K, Jacquemin MG.

Int J Lab Hematol. 2019 Aug;41(4):e79-e80. doi: 10.1111/ijlh.12970. Epub 2019 Jan 2. No abstract available.

PMID:
30600904
3.

Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.

Van den Bossche D, Toelen J, Schoeters J, Van Horenbeeck I, Vanlinthout I, Debasse M, Peerlinck K, Jacquemin M.

Haemophilia. 2019 Jan;25(1):e19-e26. doi: 10.1111/hae.13656. Epub 2018 Dec 27.

PMID:
30589148
4.

A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature.

van Dievoet MA, Jacquemin M, Van Calsteren K, Peerlinck K.

Haemophilia. 2019 Jan;25(1):e57-e59. doi: 10.1111/hae.13654. Epub 2018 Dec 3. No abstract available.

PMID:
30507056
5.

Pure ultra-fine carbon particles do not exert pro-coagulation and inflammatory effects on microvascular endothelial cells.

Dinmohammadi H, Pirdel Z, Salarilak L, Hoylaerts M, Nejatbakhsh R, Biglari A, Jacquemin M, Shahani T.

Environ Sci Pollut Res Int. 2019 Jan;26(1):991-999. doi: 10.1007/s11356-018-3783-3. Epub 2018 Nov 19.

PMID:
30456618
6.

Does haemophilia slow down the development of liver fibrosis?

van Dievoet MA, Leclercq I, Hermans C, Lambert C, Horsmans Y, Jacquemin M, Eeckhoudt S.

Haemophilia. 2019 Jan;25(1):e32-e35. doi: 10.1111/hae.13630. Epub 2018 Nov 14. No abstract available.

PMID:
30427101
7.

Measurement of factor VIII activity of efraloctocog alfa with commercially available one-stage clotting and chromogenic assays: Results from the Belgian national External Quality Assessment Scheme.

Van Blerk M, Chatelain B, Devreese K, Jacquemin M, Jochmans K, Mullier F, Soumali MR, Broeders S.

Int J Lab Hematol. 2019 Feb;41(1):e20-e22. doi: 10.1111/ijlh.12931. Epub 2018 Oct 6. No abstract available.

PMID:
30291733
8.

New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.

Van den Bossche D, Peerlinck K, Jacquemin M.

Int J Lab Hematol. 2018 May;40 Suppl 1:21-29. doi: 10.1111/ijlh.12813. Review.

PMID:
29741261
9.

Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.

Peetermans M, Liesenborghs L, Peerlinck K, Wijngaerden EV, Gheysens O, Goffin KE, Hoylaerts MF, Jacquemin M, Verhaegen J, Peetermans WE, Verhamme P, Vanassche T; Staphylothrombin Investigators.

Thromb Haemost. 2018 May;118(5):818-829. doi: 10.1055/s-0038-1639586. Epub 2018 Apr 3.

PMID:
29614521
10.

The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.

Jacquemin M, Toelen J, Feyen L, Schoeters J, Van Horenbeeck I, Vanlinthout I, Debasse M, Vanassche T, Peerlinck K, Verhamme P.

Int J Lab Hematol. 2018 Aug;40(4):442-447. doi: 10.1111/ijlh.12807. Epub 2018 Mar 24.

PMID:
29573340
11.

Biodistribution of Liver-Derived Mesenchymal Stem Cells After Peripheral Injection in a Hemophilia A Patient.

Sokal EM, Lombard CA, Roelants V, Najimi M, Varma S, Sargiacomo C, Ravau J, Mazza G, Jamar F, Versavau J, Jacobs V, Jacquemin M, Eeckhoudt S, Lambert C, Stéphenne X, Smets F, Hermans C.

Transplantation. 2017 Aug;101(8):1845-1851. doi: 10.1097/TP.0000000000001773.

PMID:
28738402
12.

Sol-gel derived lithium-releasing glass for cartilage regeneration.

Li S, Maçon ALB, Jacquemin M, Stevens MM, Jones JR.

J Biomater Appl. 2017 Jul;32(1):104-113. doi: 10.1177/0885328217706640.

13.

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Kahle J, Orlowski A, Stichel D, Healey JF, Parker ET, Jacquemin M, Krause M, Tiede A, Schwabe D, Lollar P, Königs C.

Blood. 2017 Aug 10;130(6):808-816. doi: 10.1182/blood-2016-11-751347. Epub 2017 May 15.

14.

The amplitude of coagulation curves from thrombin time tests allows dysfibrinogenemia caused by the common mutation FGG-Arg301 to be distinguished from hypofibrinogenemia.

Jacquemin M, Vanlinthout I, Van Horenbeeck I, Debasse M, Toelen J, Schoeters J, Lavend'homme R, Freson K, Peerlinck K.

Int J Lab Hematol. 2017 Jun;39(3):301-307. doi: 10.1111/ijlh.12625. Epub 2017 Mar 20.

PMID:
28318107
15.

Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.

Van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J, Jacquemin M, Jochmans K, Mullier F, Wijns W, China B, Vernelen K, Soumali MR.

Int J Lab Hematol. 2017 Aug;39(4):402-408. doi: 10.1111/ijlh.12640. Epub 2017 Mar 17.

PMID:
28304137
16.

Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors.

Jacquemin M, Vodolazkaia A, Toelen J, Schoeters J, Van Horenbeeck I, Vanlinthout I, Debasse M, Peerlinck K.

Haemophilia. 2018 Jul;24(4):675-682. doi: 10.1111/hae.13123. Epub 2017 Jan 25.

PMID:
28124445
17.

Idarucizumab for dabigatran overdose.

Peetermans M, Pollack C Jr, Reilly P, Liesenborghs L, Jacquemin M, Levy JH, Weitz JI, Verhamme P.

Clin Toxicol (Phila). 2016 Sep;54(8):644-6. doi: 10.1080/15563650.2016.1187737. Epub 2016 May 25.

PMID:
27224445
18.

Free hemoglobin: a boost to platelet thrombi.

Jacquemin M, Peerlinck K.

Blood. 2015 Nov 12;126(20):2262-3. doi: 10.1182/blood-2015-09-667642. No abstract available.

19.

T cell response to FVIII.

Jacquemin M, Saint-Remy JM.

Cell Immunol. 2016 Mar;301:8-11. doi: 10.1016/j.cellimm.2015.09.007. Epub 2015 Sep 26. Review.

PMID:
26435345
20.

The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.

Jacquemin M, Toelen J, Schoeters J, van Horenbeeck I, Vanlinthout I, Debasse M, Peetermans M, Vanassche T, Peerlinck K, van Ryn J, Verhamme P.

J Thromb Haemost. 2015 Nov;13(11):2087-92. doi: 10.1111/jth.13138. Epub 2015 Oct 5.

21.

Factor VIII inhibitor: affinity is the clue.

Jacquemin M, Peerlinck K.

Blood. 2015 Feb 12;125(7):1056-8. doi: 10.1182/blood-2014-12-618991. No abstract available.

22.

Response: Extended analysis of microarray data does not contradict preplasmablast phenotype of human CD20+CD27+CD43+ cells.

Covens K, Verbinnen B, Jacquemin M, Bossuyt X.

Blood. 2013 Nov 21;122(22):3693-4. doi: 10.1182/blood-2013-09-528091. No abstract available.

23.

Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII.

Shahani T, Covens K, Lavend'homme R, Jazouli N, Sokal E, Peerlinck K, Jacquemin M.

J Thromb Haemost. 2014 Jan;12(1):36-42. doi: 10.1111/jth.12412.

24.

Calibration of the X-ray photoelectron spectroscopy binding energy scale for the characterization of heterogeneous catalysts: is everything really under control?

Jacquemin M, Genet MJ, Gaigneaux EM, Debecker DP.

Chemphyschem. 2013 Oct 21;14(15):3618-26. doi: 10.1002/cphc.201300411. Epub 2013 Sep 5.

PMID:
24009131
25.

Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype.

Covens K, Verbinnen B, Geukens N, Meyts I, Schuit F, Van Lommel L, Jacquemin M, Bossuyt X.

Blood. 2013 Jun 27;121(26):5176-83. doi: 10.1182/blood-2012-12-471953. Epub 2013 Apr 23.

26.

Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.

Goda M, Jacobs S, Rega F, Peerlinck K, Jacquemin M, Droogne W, Vanhaecke J, Van Cleemput J, Van den Bossche K, Meyns B.

J Heart Lung Transplant. 2013 May;32(5):539-45. doi: 10.1016/j.healun.2013.02.006.

PMID:
23570742
27.

Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial.

Goossens GA, Jérôme M, Janssens C, Peetermans WE, Fieuws S, Moons P, Verschakelen J, Peerlinck K, Jacquemin M, Stas M.

Ann Oncol. 2013 Jul;24(7):1892-9. doi: 10.1093/annonc/mdt114. Epub 2013 Apr 3.

PMID:
23553060
28.

Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation.

Mahieu E, Claes K, Jacquemin M, Evenepoel P, Op De Beek K, Bogaert AM, Kuypers D, Verhamme P, Meijers B.

Artif Organs. 2013 May;37(5):482-7. doi: 10.1111/aor.12002. Epub 2013 Mar 5.

PMID:
23461610
29.

Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.

Cauchie M, Toelen J, Peerlinck K, Jacquemin M.

Haemophilia. 2013 May;19(3):e133-8. doi: 10.1111/hae.12093. Epub 2013 Feb 4.

PMID:
23374099
30.

Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors.

Carlier VA, VanderElst L, Janssens W, Jacquemin MG, Saint-Remy JM.

PLoS One. 2012;7(10):e45366. doi: 10.1371/journal.pone.0045366. Epub 2012 Oct 9.

31.

Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII.

Tangelder M, Long C, Emmerechts J, Jacquemin M, Peerlinck K, Vanassche T, Glazer S, Giesen P, Hoylaerts M, Verhamme P.

J Thromb Haemost. 2012 Jul;10(7):1371-8. doi: 10.1111/j.1538-7836.2012.04762.x.

32.

A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel.

Chen F, Maridakis V, O'neill EA, Beals C, Radziszewski W, de Lepeleire I, Van Dyck K, Depré M, Bolognese JA, de Hoon J, Jacquemin M.

Platelets. 2012;23(4):249-58. doi: 10.3109/09537104.2011.604806. Epub 2011 Sep 15.

PMID:
21919555
33.

Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis.

Emmerechts J, Vanassche T, Loyen S, Van Linthout I, Cludts K, Kauskot A, Long C, Jacquemin M, Hoylaerts MF, Verhamme P.

Thromb Res. 2012 Apr;129(4):514-9. doi: 10.1016/j.thromres.2011.06.027. Epub 2011 Jul 20.

PMID:
21777952
34.

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.

Pautard B, D'Oiron R, Li Thiao Te V, Lavend'homme R, Saint-Remy JM, Peerlinck K, Jacquemin M.

J Thromb Haemost. 2011 Jun;9(6):1163-70. doi: 10.1111/j.1538-7836.2011.04267.x.

35.

Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial.

Verhamme P, Tangelder M, Verhaeghe R, Ageno W, Glazer S, Prins M, Jacquemin M, Büller H; TB-402 Study Group.

J Thromb Haemost. 2011 Apr;9(4):664-71. doi: 10.1111/j.1538-7836.2011.04221.x.

36.

Retroviral vectors induce epigenetic chromatin modifications and IL-10 production in transduced B cells via activation of toll-like receptor 2.

Ahangarani RR, Janssens W, Carlier V, Vanderelst L, Vandendriessche T, Chuah M, Jacquemin M, Saint-Remy JM.

Mol Ther. 2011 Apr;19(4):711-22. doi: 10.1038/mt.2010.275. Epub 2010 Dec 14.

37.

A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function.

Lü J, Pipe SW, Miao H, Jacquemin M, Gilbert GE.

Blood. 2011 Mar 17;117(11):3181-9. doi: 10.1182/blood-2010-08-301663. Epub 2010 Dec 14.

38.

Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.

Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M.

Clin Ther. 2010 Jun;32(6):1205-20. doi: 10.1016/j.clinthera.2010.06.012.

PMID:
20637972
39.

Mild haemophilia: a disease with many faces and many unexpected pitfalls.

Peerlinck K, Jacquemin M.

Haemophilia. 2010 Jul;16 Suppl 5:100-6. doi: 10.1111/j.1365-2516.2010.02306.x.

PMID:
20590864
40.

Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.

Jacquemin M.

Haemophilia. 2010 May;16(102):16-9. doi: 10.1111/j.1365-2516.2010.02233.x. Review.

PMID:
20536982
41.

A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.

Dimitrov JD, Roumenina LT, Plantier JL, Andre S, Saboulard D, Meslier Y, Planchais C, Jacquemin M, Saint-Remy JM, Atanasov BP, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2010 Jul;8(7):1524-31. doi: 10.1111/j.1538-7836.2010.03878.x. Epub 2010 Mar 30.

42.

Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool.

Shahani T, Lavend'homme R, Luttun A, Saint-Remy JM, Peerlinck K, Jacquemin M.

Blood. 2010 Jun 10;115(23):4902-9. doi: 10.1182/blood-2009-07-232546. Epub 2010 Mar 29.

43.

In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness.

Ahangarani RR, Janssens W, VanderElst L, Carlier V, VandenDriessche T, Chuah M, Weynand B, Vanoirbeek JA, Jacquemin M, Saint-Remy JM.

J Immunol. 2009 Dec 15;183(12):8232-43. doi: 10.4049/jimmunol.0901777.

44.

Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody.

Dimitrov JD, Roumenina LT, Andre S, Repesse Y, Atanasov BP, Jacquemin M, Saint-Remy JM, Bayry J, Kaveri SV, Lacroix-Desmazes S.

Mol Immunol. 2009 Dec;47(2-3):290-7. doi: 10.1016/j.molimm.2009.09.021. Epub 2009 Oct 6.

PMID:
19811836
46.

A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons.

Jacquemin M, Stassen JM, Saint-Remy JM, Verhamme P, Lavend'homme R, VanderElst L, Meiring M, Pieters H, Lamprecht S, Roodt J, Badenhorst P.

J Thromb Haemost. 2009 Mar;7(3):429-37. doi: 10.1111/j.1538-7836.2008.03271.x.

47.

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.

d'Oiron R, Pipe SW, Jacquemin M.

Haemophilia. 2008 Jul;14 Suppl 3:138-46. doi: 10.1111/j.1365-2516.2008.01730.x. Review.

48.

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

Dasgupta S, Navarrete AM, André S, Wootla B, Delignat S, Repessé Y, Bayry J, Nicoletti A, Saenko EL, d'Oiron R, Jacquemin M, Saint-Remy JM, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2008 Jan;93(1):83-9. doi: 10.3324/haematol.11535.

49.
50.

A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.

Dasgupta S, Navarrete AM, Bayry J, Delignat S, Wootla B, André S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TB, Moris A, Saint-Remy JM, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8965-70. Epub 2007 May 14.

Supplemental Content

Loading ...
Support Center